NYSE · CIK 0001237831 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
GLOBUS MEDICAL, INC.
GMED chart by TradingView
PRICE HISTORY
LIVE · NYSEGMED chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $2.9B
- EBITDA
- $0.8B
- FREE CASH FLOW
- $0.6B
- EPS
- $3.92
- GROSS MARGIN
- 67.41%
- ROIC
- —
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
20.3x
+10%18.3x230.7x
⤢
P / SALES (TTM)
3.5x
-12%2.8x8.6x
⤢
P / BOOK
2.3x
-15%1.4x5.1x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
6.96%
+1.1pp1.39%7.47%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.8B
+482%⤢
EBITDA (DERIVED)
$0.3B
+555%⤢
NET INCOME
$0.2B
+478%⤢
EPS (DILUTED)
$1.10
+306%⤢
REVENUE GROWTH YOY
5.94%
+6.9pp-23.45%124.60%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
22.36%
-4.2pp3.93%29.40%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
11.23%
-3.3pp1.02%14.52%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN69.42%
OPERATING MARGIN23.10%
NET MARGIN19.20%
FCF MARGIN22.36%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.2B
+389%⤢
STOCK-BASED COMP
$0.0B
+387%⤢
CAPITAL EXPENDITURE
$0.0B
+406%⤢
SHARES OUTSTANDING
0.14B
+42%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.5B
+463%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 87.96%INSIDERS 0.61%OTHER / RETAIL 11.42%795 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 7.73% | 10.5M | $864.5M | +2.1% |
| Janus Henderson Group PLC | 5.62% | 7.6M | $627.8M | +4.5% |
| Vanguard Capital Management LLC | 3.71% | 5.0M | $414.4M | NEW |
| Vanguard Portfolio Management LLC | 3.59% | 4.9M | $401.8M | NEW |
| Invesco Ltd. | 3.18% | 4.3M | $355.5M | +11.1% |
| State Street Corporation | 2.64% | 3.6M | $295.7M | +3.6% |
| Sculptor Capital LP | 2.25% | 3.1M | $251.8M | +1.9% |
| JPMORGAN CHASE & CO | 1.91% | 2.6M | $213.7M | -16.3% |
| Bank of Montreal /CAN/ | 1.70% | 2.3M | $190.0M | -31.6% |
| Geode Capital Management, LLC | 1.56% | 2.1M | $173.9M | +2.7% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.